Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Sintilimab Injection Plus Chemo Improves PFS in Frontline Nonsquamous NSCLC

Gina Columbus
Published: Monday, Jan 13, 2020

Li Zhang, MD

Li Zhang, MD

The first-line combination of sintilimab injection (Tyvyt) plus pemetrexed (Alimta) and platinum-based therapy showed a statistically significant improvement in progression-free survival (PFS) compared with chemotherapy and placebo in patients with advanced or recurrent nonsquamous non–small cell lung cancer (NSCLC) who did not harbor EGFR or ALK abnormalities, according to an interim analysis of the phase III ORIENT-11 trial (NCT03607539).1

In the Chinese study, results showed that the combination met the predefined efficacy criteria of the interim analysis, which was conducted by the Independent Data Monitoring Committee (IDMC). The safety profile of sintilimab injection was found to be consistent with prior studies, and no new safety signals were identified.

Further findings will be presented at an upcoming medical meeting. Based on a recommendation from the IDMC, Eli Lilly and Company and Innovent, the companies that are jointly developing sintilimab and pemetrexed, stated that they will initiate regulatory discussions with the National Medical Products Administration (NMPA) in China in the near future.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication